CKD合并终末期肾病的癌症患者的贫血管理

IF 2 3区医学 Q2 UROLOGY & NEPHROLOGY

Advances in chronic kidney disease Pub Date : 2022-03-01 DOI:10.1053/j.ackd.2022.03.005

Arash Rashidi , Pranav S. Garimella , Abdullah Al-Asaad , Talar Kharadjian , Mariela Navarro Torres , Jyotsana Thakkar

{"title":"CKD合并终末期肾病的癌症患者的贫血管理","authors":"Arash Rashidi , Pranav S. Garimella , Abdullah Al-Asaad , Talar Kharadjian , Mariela Navarro Torres , Jyotsana Thakkar","doi":"10.1053/j.ackd.2022.03.005","DOIUrl":null,"url":null,"abstract":"<div><p>Anemia is a common medical problem<span><span> among patients with cancer and chronic kidney disease (CKD). Although anemia </span>in patients<span> with CKD is often treated with iron and erythropoietin-stimulating agents, there are controversies with regard to the use of erythropoietin-stimulating agents in cancer patients. In this article, we review the treatment of anemia in patients with cancer and CKD, in addition to summarizing the current guidelines in treatment of anemia in these patients.</span></span></p></div>","PeriodicalId":7221,"journal":{"name":"Advances in chronic kidney disease","volume":"29 2","pages":"Pages 180-187.e1"},"PeriodicalIF":2.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease\",\"authors\":\"Arash Rashidi , Pranav S. Garimella , Abdullah Al-Asaad , Talar Kharadjian , Mariela Navarro Torres , Jyotsana Thakkar\",\"doi\":\"10.1053/j.ackd.2022.03.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Anemia is a common medical problem<span><span> among patients with cancer and chronic kidney disease (CKD). Although anemia </span>in patients<span> with CKD is often treated with iron and erythropoietin-stimulating agents, there are controversies with regard to the use of erythropoietin-stimulating agents in cancer patients. In this article, we review the treatment of anemia in patients with cancer and CKD, in addition to summarizing the current guidelines in treatment of anemia in these patients.</span></span></p></div>\",\"PeriodicalId\":7221,\"journal\":{\"name\":\"Advances in chronic kidney disease\",\"volume\":\"29 2\",\"pages\":\"Pages 180-187.e1\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in chronic kidney disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1548559522000556\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in chronic kidney disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1548559522000556","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 2

摘要

贫血是癌症和慢性肾脏疾病(CKD)患者常见的医学问题。虽然CKD患者的贫血通常用铁和促红细胞生成素治疗，但在癌症患者中使用促红细胞生成素仍存在争议。在这篇文章中，我们回顾了癌症和CKD患者贫血的治疗，并总结了目前治疗这些患者贫血的指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease

查看原文本刊更多论文

Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease

Anemia is a common medical problem among patients with cancer and chronic kidney disease (CKD). Although anemia in patients with CKD is often treated with iron and erythropoietin-stimulating agents, there are controversies with regard to the use of erythropoietin-stimulating agents in cancer patients. In this article, we review the treatment of anemia in patients with cancer and CKD, in addition to summarizing the current guidelines in treatment of anemia in these patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in chronic kidney disease 医学-泌尿学与肾脏学

自引率

3.40%

发文量

审稿时长

11.1 weeks

期刊介绍： The purpose of Advances Chronic Kidney Disease is to provide in-depth, scholarly review articles about the care and management of persons with early kidney disease and kidney failure, as well as those at risk for kidney disease. Emphasis is on articles related to the early identification of kidney disease; prevention or delay in progression of kidney disease